South Africa has received its first shipment of Lenacapavir, a ground-breaking HIV prevention medicine that could transform the country’s fight against the virus.
The Department of Health confirmed on Tuesday that 37 920 doses of the injectable drug arrived in the country last Thursday, marking a significant milestone in HIV prevention efforts.
Lenacapavir is administered twice yearly to HIV-negative individuals and is considered one of the most effective pre-exposure prophylaxis options available. The medicine is particularly significant for South Africa, which bears the world’s highest HIV burden.
“This is part of integrated, differentiated and people-centred HIV prevention services, offering new hope for people who face barriers to existing HIV prevention methods,” the Department of Health said in a statement.
The drug is expected to improve adherence amongst vulnerable priority groups, including adolescent girls and young women, sex workers, and men having sex with men.
Health Minister Aaron Motsoaledi will announce the official launch date in consultation with President Cyril Ramaphosa. The department said a phased implementation plan would accompany the launch.
“Lenacapavir will boost the country’s efforts to reduce new HIV infections to end AIDS as a public health threat by 2030,” the department added.
ALSO READ: Groundbreaking HIV prevention shots begin rolling out across Africa
The South African National AIDS Council has welcomed the arrival and confirmed it is working on local manufacturing initiatives. SANAC CEO Dr Thembisile Xulu, who chairs the Ad Hoc Committee on Lenacapavir Voluntary Licensing, said local production would enhance sustainability and affordability.
“South Africa’s pioneering of local manufacturing represents an important step towards strengthening the region and the continent’s capacity to expand sustainable access to life-saving health commodities,” Xulu said.
Deputy President Paul Mashatile first announced plans for local manufacturing discussions during World TB Day commemorations on 24 March in the Western Cape.
The medicine is described as preventive rather than a vaccine and has been hailed as one of the most exciting HIV prevention advances in recent years.
SANAC said further details about licensing processes would be provided during the official public launch, which will be announced soon.
ALSO READ: HIV-prevention drug to be available for $40 a year from 2027
